Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
PODD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$173.00 - $329.33
Previous CloseN/A
Volume86.50K
Average Volume (3M)590.61K
Market Cap
$19.51B
Enterprise Value$19.87B
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$1.70B
Price to Earnings (P/E)92.3
Beta1.09
Next Earnings
Oct 30, 2025EPS Estimate
1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.17
Shares Outstanding70,374,920
10 Day Avg. Volume618,448
30 Day Avg. Volume590,609
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)15.10
Price to Sales (P/S)8.83
P/FCF Ratio59.90
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue9.04
Enterprise Value/Gross Profit12.84
Enterprise Value/Ebitda47.51
Forecast
1Y Price Target
$347.89Price Target Upside14.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Bulls Say, Bears Say
Bulls Say
EarningsPODD posted a stellar Q2, with revenue and EPS exceeding estimates.
International ExpansionInternationally, O5 is approved in 14 of 25 international markets, with more expansion planned in the coming quarters.
Product DifferentiationPODD supports increased access to the latest technology for diabetes management.
Sales GrowthQ3 sales growth outlook is well above the Street target, at 22-25% vs 19%.
Bears Say
Competitive BiddingThe latest message from PODD is that PODD does not believe that automated insulin delivery systems available via Medicare Part D should be eligible for competitive bidding under Part B.
Gross MarginsLower SG&A expenses contributed to an EPS beat, despite lower gross margins.
Insulet News
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $173.00 and its highest was $329.33 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $19.51B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Oct 30, 2025 which is in 83 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Aug 07, 2025. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.14.
How many shares outstanding does Insulet have?
Insulet has 70,374,920 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.17 in its last earnings report, beating expectations of $0.92. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
Insulet Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$347.89 (14.61% Upside)
$347.89 (14.61% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 571.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.43%
12-Months-Change
Fundamentals
Return on Equity
19.18%
Trailing 12-Months
Asset Growth
20.39%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD Company Deck
PODD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, highlighted by significant revenue growth, expansion in international markets, and an increase in the prescriber base. The company also raised its full-year guidance, reflecting strong performance and confidence in future growth. However, there were some financial challenges, such as inventory-related charges and increased interest expenses. Overall, positive aspects significantly outweighed the negatives.View all PODD earnings summariesPODD Revenue Breakdown
74.73% U.S.
25.27% International
PODD Stock 12 Month Forecast
Average Price Target
$347.89
▲(14.61% Upside)
Technical Analysis
Ownership Overview
0.37% Insiders
43.32% Mutual Funds
1.15% Other Institutional Investors
28.40% Public Companies and Individual Investors